All In Biotech

Drug Trial Radar · NCT02152761

Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery

A 24-week Double-blind Treatment and 24-week Follow-up, Randomized, Multicenter, Placebo-controlled, Phase IIa/IIb Study to Evaluate Safety and Efficacy of i.v. Bimagrumab on Total Lean Body Mass and Physical Performance in Patients After Surgical Treatment of Hip Fracture

Last checked: Nov 19, 2026Latest source record: Aug 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 251 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

251

Actual

Start

Sep 16, 2014

Primary completion

May 14, 2018

Study completion Oct 25, 2018

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jun 2, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to assess if bimagrumab is safe and effective in patients with muscle wasting (atrophy) after hip fracture surgery.

Conditions

  • Muscle Wasting (Atrophy) After Hip Fracture Surgery

Interventions

  • bimagrumabDrug

    Bimagrumab was administered as intravenous infusion starting on Day 1 until week 20.

  • placeboOther

    Matching placebo was administered as intravenous infusion starting on Day 1 until week 20.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Total Lean Body Mass Measured by DXA (Dual-energy X-ray Absorptiometry) at Weeks 12 and 24Time frame: baseline, weeks 12 and 24

Locations

53 sites in 19 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    El Cajon, California

  • Novartis Investigative Site

    Denver, Colorado

  • Novartis Investigative Site

    Gainesville, Georgia

  • Novartis Investigative Site

    Rochester, Minnesota

  • Novartis Investigative Site

    New York, New York

  • Novartis Investigative Site

    Ciudad Autonoma de Bs As, Argentina

  • Novartis Investigative Site

    Bedford Park, South Australia, Australia

  • Novartis Investigative Site

    Graz, Austria

  • Novartis Investigative Site

    Bruges, Belgium

  • Novartis Investigative Site

    Genk, Belgium

  • Novartis Investigative Site

    Ghent, Belgium

  • Novartis Investigative Site

    Santiago, Chile

  • Novartis Investigative Site

    Barranquilla, Colombia

  • Novartis Investigative Site

    Cali, Valle del Cauca Department, Colombia

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Brno, Czech Republic, Czechia

  • Novartis Investigative Site

    Hradec Králové, Czech Republic, Czechia

  • Novartis Investigative Site

    Pardubice, Czech Republic, Czechia

  • Novartis Investigative Site

    Pilsen, Czech Republic, Czechia

  • Novartis Investigative Site

    Prague, Czech Republic, Czechia

  • Novartis Investigative Site

    Lille, France

  • Novartis Investigative Site

    Montpellier, France

  • Novartis Investigative Site

    Bad Abbach, Germany

  • Novartis Investigative Site

    Dresden, Germany

  • Novartis Investigative Site

    Magdeburg, Germany

  • Novartis Investigative Site

    Würzburg, Germany

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Hatvan, Hungary

  • Novartis Investigative Site

    Nishinomiya, Hyōgo, Japan

  • Novartis Investigative Site

    Kamakura, Kanagawa, Japan

  • Novartis Investigative Site

    Kochi, Kochi, Japan

  • Novartis Investigative Site

    Kumamoto, Kumamoto, Japan

  • Novartis Investigative Site

    Okayama, Okayama-ken, Japan

  • Novartis Investigative Site

    Toyama, Toyama, Japan

  • Novartis Investigative Site

    Aguascalientes, Mexico

  • Novartis Investigative Site

    San Luis Potosí City, Mexico

  • Novartis Investigative Site

    Saint Petersburg, Russia

  • Novartis Investigative Site

    Saint Petersburg, Russia

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.